Lexicon Pharmaceuticals, Inc. Forecast, price target & analysts
Lexicon Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Lexicon Pharmaceuticals, Inc. Classifications & Recommendation:
Lexicon Pharmaceuticals, Inc. Price Target
| Target Price | $3.60 |
| Price | $0.67 |
| Potential |
437.31%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Lexicon Pharmaceuticals, Inc. 2026 .
The average Lexicon Pharmaceuticals, Inc. target price is $3.60.
This is
437.31%
register free of charge
$10.00
1,392.54%
register free of charge
$0.80
19.40%
register free of charge
|
|
| A rating was issued by 7 analysts: 5 Analysts recommend Lexicon Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Lexicon Pharmaceuticals, Inc. stock has an average upside potential 2026 of
437.31%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.20 | 11.13 |
| 757.14% | 827.60% | |
| EBITDA Margin | -14,266.67% | -2,008.78% |
| 80.09% | 85.92% | |
| Net Margin | -24,099.33% | -2,205.14% |
| 84.95% | 90.85% |
6 Analysts have issued a sales forecast Lexicon Pharmaceuticals, Inc. 2024 . The average Lexicon Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Lexicon Pharmaceuticals, Inc. EBITDA forecast 2024. The average Lexicon Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Lexicon Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average Lexicon Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.80 | -0.68 |
| 29.03% | 15.00% | |
| P/E | negative | |
| EV/Sales | 8.06 |
6 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast for earnings per share. The average Lexicon Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Lexicon Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Lexicon Pharmaceuticals, Inc....
Current Lexicon Pharmaceuticals, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 29 2025 |
| Needham | Locked ➜ Locked | Locked | Jan 29 2025 |
| Needham | Locked ➜ Locked | Locked | Dec 23 2024 |
| Needham | Locked ➜ Locked | Locked | Nov 25 2024 |
| Needham | Locked ➜ Locked | Locked | Nov 22 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 13 2024 |
| Needham | Locked ➜ Locked | Locked | Nov 13 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 29 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Jan 29 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Dec 23 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Nov 25 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Nov 22 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 13 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Nov 13 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
